News and information covering research and development.
- Oncology losing special status with payers
A recent IMS Consulting Pricing & Reimbursement conference discussed the issues surrounding the expense of providing new cancer therapies.
Aug 1, 2006
- Looking to the East for New Active Substances
The number of NASs launched dropped again in 2005, to 30, but Japan's productivity improved and China is still showing potential.
May 8, 2006
- Antithrombotics – Current Market and Future Outlook
The antithrombotics market is growing quickly from a relatively low base. Dollar sales have more than doubled in the past five years and there is considerable potential for further growth.
Jul 1, 2005
- New Active Substances Plateau in 2004
Just one more new drug was launched in 2004 over 2003, but there were signs of a growing contribution from new regions.
May 23, 2005
- Foresight or Folly? Generics Firms Foray Into NCEs
IMS examines the increasing investment in R&D by companies that have traditionally focused on generic copies. Despite flourishing generic sales they are prepared to take the risks in order to win high returns.
Sep 30, 2004
- Could Cymbalta Bring Cheer for Lilly?
After a series of delays caused by problems at its manufacturing plant Lilly's new SNRI antidepressant Cymbalta finally received FDA approval in August 2004 - IMS looks at the market.
Aug 18, 2004
- Ocular Drugs: Light at the End of the Tunnel
Big pharma has been guilty of ignoring ophthalmology drug development in the past but the situation is changing with companies like Novartis and Pfizer leading the renaissance.
Jun 22, 2004
- Statin Self-Medication Arrives in the UK
In a widely heralded move the UK Health Secretary has granted over-the-counter status for Merck & Co's cholesterol reducer Zocor the first statin to be sold without a prescription.
May 26, 2004
- Generics: Moving Up the Value Chain to Higher Priced Products
The take home message from IIR's Global Generic Strategies conference March 2004 was that the traditional line between R&D and generic firms is blurring as companies realise the benefits of a mixed portfolio.
May 18, 2004
- Biogenerics: A Difficult Birth?
PPR Communications reports on the discussions over approvals of biogeneric products a hot topic at the IIR Global Generic Strategies conference held in Barcelona in March 2004.
May 18, 2004
